Logo

American Heart Association

  13
  0


Final ID: MP2737

Eicosapentaenoic Acid Attenuates Oxidation of Lp(a) and other Atherogenic Lipoproteins by a Potential Scavenging Mechanism

Abstract Body (Do not enter title and authors here): Background: Lipoprotein(a) (Lp(a)) is an ApoB-containing particle, and the primary carrier of oxidized phospholipid linked to increased cardiovascular (CV) risk. The oxPL may induce rapid lipid oxidation compared with other ApoB particles. The omega-3 fatty acid (n-3FA) EPA (20:5) delivered as icosapent ethyl (4 g/d) reduced CV events in high-risk patients, including those with elevated Lp(a) (REDUCE-IT).
Hypothesis: We suspect EPA blunts lipid oxidation via the 5 methylene-interrupted alkene bonds on EPA, and this structure favors radical scavenging in lipoprotein particles – including Lp(a) – more than comparable agents at pharmacologic concentrations.
Methods: Lp(a), small dense LDL (sdLDL), and TG-rich lipoproteins (VLDL) were enriched to 66% of total ApoB-containing particles (the remaining 34% being LDL) from patients following isopycnic centrifugation. Lp(a), sdLDL, pure LDL, and VLDL were matched for total protein (50 µg/mL) and incubated at 37°C for 30 min in the absence or presence of EPA (50 µM). Samples then underwent copper sulfate-induced oxidation monitored by formation of malondialdehyde (MDA) for 4 h. The antioxidant effects of EPA were then compared with the lipophilic scavenging agent, probucol. We also deliberately oxidized EPA and the n-3FA alpha-linolenic acid (ALA, 18:3) to damage alkene bonds and correlated this with antioxidant activity.
Results: Lp(a)-enriched plasma underwent significantly more rapid oxidation than the other fractions (58% of total lipid was oxidized at 0.5 h compared with 28% of sdLDL-enriched, 18% of pure LDL, and 6% VLDL) and EPA attenuated oxidation of all particles >63% at the time peak oxidation levels were reached for each fraction (all p<0.001). At these times, probucol reduced MDA levels 20%, 21%, and 85% in Lp(a), sdLDL, and LDL, respectively (all p<0.05) but not in VLDL. EPA exerted significantly more antioxidant action than ALA when undamaged, while oxidation of EPA and ALA – evidenced by increased lipid oxidation markers – reduced their antioxidant capacity.
Conclusions: In Lp(a)-enriched plasma, Lp(a) underwent more rapid oxidation than other ApoB-containing particles. EPA attenuated oxidation of all particles at pharmacologic levels in contrast with other lipid-centric antioxidants tested, which is consistent with a radical scavenging mechanism. The potent inhibition of Lp(a) oxidation by EPA may contribute to the benefit observed in REDUCE-IT, including those subjects with elevated Lp(a) levels.
  • Sherratt, Samuel  ( Mount Sinai Fuster Heart Hospital , Scarsdale , New York , United States )
  • Libby, Peter  ( Brigham and Womens Hospital , Beverly , Massachusetts , United States )
  • Dunbar, Richard  ( Amarin Pharma, Inc. , Bridgewater , New Jersey , United States )
  • Bhatt, Deepak  ( Mount Sinai Fuster Heart Hospital , Scarsdale , New York , United States )
  • Mason, Preston  ( Brigham and Womens Hospital , Beverly , Massachusetts , United States )
  • Author Disclosures:
    Samuel Sherratt: DO have relevant financial relationships ; Employee:Elucida Research:Active (exists now) ; Speaker:Novartis:Past (completed) | Peter Libby: DO have relevant financial relationships ; Advisor:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Novartis, Novo Nordisk, Genentech:Past (completed) ; Executive Role:XBiotech, Inc:Active (exists now) ; Executive Role:Soley Thereapeutics - financial interest:Active (exists now) ; Other (please indicate in the box next to the company name):TenSixteen Bio - financial interest:Active (exists now) ; Advisor:Polygon Therapeutics:Active (exists now) ; Advisor:PlaqueTec:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Olatec Therapeutics:Active (exists now) ; Advisor:Kowa Pharmaceuticals:Active (exists now) ; Advisor:Kancera:Active (exists now) ; Advisor:Elucid Bioimaging:Active (exists now) ; Advisor:CSL Behring:Active (exists now) ; Advisor:Caristo Diagnostics:Active (exists now) | Richard Dunbar: No Answer | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Advisory Board: Angiowave, Antlia Bioscience, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, NirvaMed, Novo Nordisk, Repair Biotechnologies, Stasys, Tourmaline Bio:Active (exists now) ; Individual Stocks/Stock Options:Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Cleerly.:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease);:Active (exists now) ; Researcher:Research Funding: Abbott, Acesion Pharma, Afimmune, Alnylam, Amarin, Amgen, AstraZeneca, Atricure, Bayer, Boehringer Ingelheim, Boston Scientific, CellProthera, Cereno Scientific, Chiesi, Cleerly, CSL Behring, Faraday Pharmaceuticals, Fractyl, Idorsia, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, MiRUS, Moderna, Novartis, Novo Nordisk, Pfizer, PhaseBio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Other: Clinical Cardiology (Deputy Editor); Progress in Cardiovascular Diseases (Deputy Editor);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Duke Clinical Research Institute, Engage Health Media, HMP Global (Editor in Chief, Journal of Invasive Cardiology), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Philips (Becker's Webinar on AI), Population Health Research Institute, WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research, Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Consultant: Alnylam, Altimmune, Broadview Ventures, Corcept Therapeutics, Corsera, GlaxoSmithKline, Hims, SERB, SFJ, Summa Therapeutics, Worldwide Clinical Trials:Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) | Preston Mason: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Atherosclerosis and Vascular Diseases: New Molecular and Cellular Mechanisms

Monday, 11/10/2025 , 01:45PM - 02:40PM

Moderated Digital Poster Session

More abstracts on this topic:
Dietary 7-ketocholesterol exacerbates post-myocardial infarction left ventricular remodeling in mice through macrophage-mediated inflammation

Katsuki Shunsuke, Matoba Tetsuya, Kawahara Takuro, Uchikawa Tomoki, Mizokami Genryu, Tabuchi Takuya, Hino Rissei, Kimura Mitsukuni, Abe Kohtaro

Eicosapentaenoic Acid (EPA) Limits Lipoprotein(a) Oxidation and its Related Effects on Endothelial Cell Stress Response Protein Expression

Sherratt Samuel, Libby Peter, Dunbar Richard, Bhatt Deepak, Mason Preston

You have to be authorized to contact abstract author. Please, Login
Not Available